ACR2015

Can Biologic DMARDs Protect Against Sepsis?

By November 11, 2015

Biologic DMARDs (bDMARDs) confer a protective effect in patients with rheumatoid arthritis, lowering risk of developing sepsis as well as reducing mortality after serious infection and sepsis, according to results from a German registry presented at the 2015 ACR/ARHP Annual Meeting.

Methotrexate May Boost Golimumab in Psoriatic Arthritis

By November 11, 2015

Adding methotrexate (MTX) to golimumab (GLM) therapy might significantly improve some symptoms among patients diagnosed with psoriatic arthritis (PsA), suggests a study reported at the 2015 ACR/ARHP Annual Meeting.

Mavrilimumab Effective Long-Term in RA Disease Activity

By November 11, 2015

Long-term administration of mavrilimumab is safe and offers sustained clinical efficacy against moderate-to-severe rheumatoid arthritis (RA), according to an open-label extension study reported at the 2015 ACR/ARHP Annual Meeting

Is Non-TNF Targeted Tx Better Than a Second Anti-TNF Drug?

By November 11, 2015

A non-TNF-targeted biologic showed better efficacy than a second anti-TNF agent for patients with rheumatoid arthritis and insufficient response to TNF-inhibitors, according to research presented at the 2015 ACR/ARHP Annual Meeting.

Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Flares?

By November 11, 2015

Dietary omega-3 fatty acid-rich fish consumption, but not omega-3 supplements alone, confer a protective effect against recurrent gout attacks, reported MaryAnn Zhang, MD, from the Boston University School of Medicine, Boston, MA, at the 2015 ACR/ARHP Annual Meeting.

Skin Tests Predict Anti-TNF Hypersensitivity Reactions in RA, AS Patients

By November 11, 2015

Patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) who develop hypersensitivity reactions to infliximab, etanercept and adalimumab are more likely to have positive skin tests despite the absence of an overall relationship with antidrug antibody (ADA) levels, according to a study reported at the 2015 ACR/ARHP Annual Meeting.

Golimumab Improves QoL, Work Productivity in Axial Spondyloarthritis

By November 11, 2015

Data presented at the 2015 ACR/ARHP Annual Meeting showed that patients with active nonradiographic axial spondyloarthritis who received golimumab showed greater improvement in quality of life and work productivity outcomes than placebo.

No 'Significant Renal Safety Signals' With Tabalumab in SLE

By November 11, 2015

Treatment with tabalumab did not significantly affect serum creatinine, glomerular filtration rate, or urine protein/creatinine ratio over 52 weeks vs. placebo, investigators reported at the 2015 ACR/ARHP Annual Meeting.

Golimumab Reduces Symptom Severity in Ankylosing Spondylitis

By November 11, 2015

Golimumab was well tolerated and effective in reducing symptom severity and improving disease outcomes in patients with ankylosing spondylitis over 12 months, a Canadian longitudinal study reported at the 2015 ACR/ARHP Annual Meeting.

PDE5 Inhibitors Beneficial in Raynaud's Phenomenon

By November 11, 2015

Phosphodiesterase 5 (PDE5) inhibitors appear to be effective in treating Raynaud's phenomenon secondary to scleroderma, investigators concluded at the 2015 ACR/ARHP Annual Meeting.

Pregabalin Safe in Fibromyalgia Whether Baseline Pain Moderate or Severe

By November 11, 2015

The safety and tolerability of pregabalin for the treatment of fibromyalgia-associated pain does not differ by baseline pain severity, a pooled analysis of five phase 3 clinical trials presented at the 2015 ACR/ARHP Annual Meeting has shown.

Apremilast Safe, Effective at 3 Years in Psoriatic Arthritis

By November 11, 2015

Longer-term efficacy and safety data from the Phase 3 PALACE 1 study have confirmed that apremilast continues to demonstrate sustained and clinically meaningful improvements in psoriatic arthritis signs and symptoms at 3 years in patients who remained on the treatment, investigators concluded at the 2015 ACR/ARHP Annual Meeting.

Ustekinumab Beneficial in Patients With Psoriatic Arthritis with Spondylitis and Peripheral Joint Involvement

By November 11, 2015

Ustekinumab (UST) benefits patients with psoriatic arthritis (PsA) with spondylitis and peripheral joint involvement, according to an post-hoc analysis of results from the PSUMMIT 1 & 2 phase 3 double-blind, placebo-controlled clinical trials, reported at the 2015 ACR/ARHP Annual Meeting.

Analysis: No Cardiovascular Benefits for Xanthine Oxidase Inhibitors

By November 10, 2015

Xanthine oxidase inhibitors (XOIs) do not improve uric acid-associated risks for cardiovascular events or deaths among adults, according to a meta-analysis of data pooled from 61 randomized controlled clinical studies, which was reported at the 2015 ACR/ARHP Annual Meeting.

IV to SC Abatacept Switch Might Diminish Efficacy for Some RA Patients

By November 10, 2015

Transitions from intravenous to subcutaneous administration of abatacept may be associated with diminished disease control in some patients with rheumatoid arthritis (RA), according to a study reported at the 2015 ACR/ARHP Annual Meeting.

Do Pre-Pregnancy Biologic DMARDs Increase the Risk of Birth Defects?

By November 10, 2015

In women with long-standing rheumatic disease there was "no significantly increased risk of malformations or other harmful consequences" in those "exposed to biologic disease-modifying antirheumatic drugs (bDMARDs) before or at conception," results of a study reported at the 2015 ACR/ARHP Annual Meeting have found.

Golimumab Reduces Burden of Illness in Psoriatic Arthritis

By November 10, 2015

Golimumab ameliorated the significant burden of illness observed in psoriatic arthritis at treatment initiation, reducing symptom severity and improving disease outcomes over 12 months, a study of patients in routine clinical practice in Canada presented at the 2015 ACR/ARHP Annual Meeting has found.

Among All Chronic Arthritides, Golimumab Drug Survival High at 2 Years

By November 10, 2015

Golimumab appears to have similar drug survival at two years in different chronic arthritides regardless of prior biological disease modifying drug (bDMARD) treatment, results of a multicenter prospective observational study reported at the 2015 ACR/ARHP Annual Meeting.

Colchicine May Prevent Acute Cardiovascular Events in Gout Patients

By November 10, 2015

In patients with gout, chronic colchicine use has no effect on the rate of incident coronary artery disease (CAD), a study presented at the 2015 ACR/ARHP Annual Meeting concluded.

Canakinumab Effective for Long-term Management of Acute Gouty Arthritis Flares

By November 10, 2015

The selective human anti-interleukin-1β antibody canakinumab demonstrates long-term safety and efficacy for patients with acute gouty arthritis flares, according to a follow-up study reported at the 2015 ACR/ARHP Annual Meeting.

Subcutaneous Methotrexate Underutilized for RA, Study Finds

By November 10, 2015

Methotrexate is frequently under-dosed, administered for an inadequate duration, and rarely switched to subcutaneous injection prior to initiating biologic therapy, James R. O'Dell, MD, from the University of Nebraska Medical Center, Omaha, NE, reported at the 2015 ACR/ARHP Annual Meeting.

Etanercept vs. Biosimilar: Which is More Effective?

By November 10, 2015

The efficacy and safety profiles of SB4, an etanercept biosimilar, were comparable to those of etanercept in patients with moderate to severe rheumatoid arthritis (RA) to Week 52, according to study findings presented at the 2015 ACR/ARHP Annual Meeting.

Study Compares Long-Term Efficacy, Safety of Infliximab Biosimilar to Reference Drug in RA

By November 10, 2015

At the 2015 ACR/ARHP Annual Meeting, study investigators reported that SB2, an infliximab biosimilar, demonstrated comparable long-term efficacy, safety, and immunogenicity to that of the infliximab reference product up to 54 weeks in patients with moderate to severe rheumatoid arthritis (RA).

Investigational Selective IL-23p19 Inhibitor Superior to Ustekinumab in PASI Response in Plaque Psoriasis

By November 10, 2015

Treatment with BI 655066, a selective IL-23p19 inhibitor, resulted in PASI responses superior to ustekinumab in patients with moderate-to-severe plaque psoriasis with or without concurrent diagnosed or suspected psoriatic arthritis, Howard Sofen, MD, from the UCLA School of Medicine, reported at the 2015 ACR/ARHP Annual Meeting.

Ixekizumab Significantly Improves QoL in Psoriatic Arthritis

By November 10, 2015

Patients with active psoriatic arthritis who were biologic disease-modifying antirheumatic drug (bDMARD)-naive had significantly improved quality of life, physical function, and work productivity following treatment with ixekizumab, investigators reported at the 2015 ACR/ARHP Annual Meeting.

Secukinumab Provides Sustained Improvements in Psoriatic Arthritis Symptoms

By November 10, 2015

Long-term efficacy and safety data have confirmed that secukinumab provides sustained improvements in psoriatic arthritis, a study reported at the 2015 ACR/ARHP Annual Meeting.

Adding TNF Inhibitors to MTX Superior to Triple Therapy in RA after Inadequate MTX Response

By November 10, 2015

Among patients diagnosed with rheumatoid arthritis (RA) that does not adequately respond to methotrexate (MTX), adding tumor necrosis factor inhibitors (TNFi) therapy yields better symptom control than triple therapy (MTX + hydroxychloroquine + sulfasalazine), according to a meta-analysis of randomized controlled trials reported at the 2015 ACR/ARHP Annual Meeting.

Efficacy of TNF Inhibitor vs. Non-TNF Inhibitor Monotherapy Compared in RA

By November 10, 2015

According to study results presented at the 2015 ACR/ARHP Annual Meeting, initiating non-TNF inhibitor monotherapy had similar or better efficacy compared with initiation of TNF inhibitor monotherapy in patients with rheumatoid arthritis.

Olokizumab Well-tolerated in RA after Anti-TNF Failure

By November 09, 2015

The investigational agent olokizumab is well-tolerated, with "a safety profile expected for this class of agent" among patients with rheumatoid arthritis (RA) for whom previous anti-tumor necrosis factor (TNF) therapy had failed, according to data from two open-label extension studies presented at the 2015 ACR/ARHP Annual Meeting.

Novel Cannabinoid Suppresses TNF-α, IFN-α in Patients with Dermatomyositis

By November 09, 2015

The synthetic, nonpsychoactive cannabinoid ajulemic acid shows early promise as a potential alternative therapy for dermatomyositis, according to a study reported at the 2015 ACR/ARHP Annual Meeting.